stockrowC4 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.9 million, up 1.02% from fiscal 2024.
- Revenue
- −24.6%
- EPS
- +63.5%
- Free cash flow
- +17.9%
Quarter to September 2026, against a year earlier
Follow CCCC
Alert me
C4 Therapeutics, Inc. (CCCC) Return on invested capital
C4 Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −279.8%, up 614.8 percentage points from fiscal 2025 (−894.6%). Over the past ten years it has ranged from −894.6% (fiscal 2025) to 0.00% (fiscal 2024) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −894.6% | (894.58) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 329.60 |
| FY2022 | −329.6% | (274.06) |
| FY2021 | −55.5% | (55.54) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ALEC Alector, Inc. compare | 0.00% |
| RZLT Rezolute, Inc. compare | 0.00% |
| EDIT Editas Medicine, Inc. compare | 0.00% |
| SRZN Surrozen, Inc. compare | 0.00% |
| ALT Altimmune, Inc. compare | −34.3% |
| AVTX Avalo Therapeutics, Inc. compare | −137.8% |
| CCCC C4 Therapeutics, Inc. | −279.8% |
| MPLT MapLight Therapeutics, Inc. compare | −348.4% |
| LYEL Lyell Immunopharma, Inc. compare | −1,070.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)